// App-Quantinova.ai

: Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study

Researchers

Presenter

  • Olivier Sitbon

Principal Investigators

  • Kelly M. Chin

  • Richard N. Channick

  • Lilla Di Scala

  • Sean Gaine

  • Hossein-Ardeschir Ghofrani

  • Irene M. Lang

  • Vallerie V. Mclaughlin

  • Ralph Preiss

  • Lewis J. Rubin

  • Grald Simonneau

  • Victor Tapson

  • Nazzareno Gali

  • Marius M. Hoeper

Medical Centers

  • Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin–Bicêtre, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Université Paris-Sud, Le Kremlin–Bicêtre, INSERM Unité 999, Le Plessis Robinson, Paris, France

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • Anesthesiology and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, United States

  • Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

  • National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland,

  • University of Giessen and Marburg Lung Center (UGMLC) and German Center of Lung Research, Giessen, Germany; Imperial College London, Department of Medicine, London, United Kingdom

  • Division of Oncology, Medical University of Graz, Graz, Austria

  • Departement of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States

  • Cedars Sinai Medical Center, Los Angeles, California, United States

  • Department of Experimental, Diagnostic and Specialty Medicine. University of Bologna, Bologna, Italy.

  • Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover, Germany,

Locations

  • France

  • United States

  • Switzerland

  • Ireland

  • United Kingdom

  • Austria

  • Italy

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Prostacyclin

  • Selexipag

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved